The Efficacy and Safety of Sanfujiu on Patients With Persistent Allergic Rhinitis: Randomized Controlled Study

Guangdong Provincial Hospital of Traditional Chinese Medicine

Status and phase: Unknown; Phase 3

Conditions: Allergic Rhinitis

Treatments: Drug: Sanfujiu; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02192645

SPAR

Details and patient eligibility

About

The purpose of this study is to determine whether Sanfujiu is effective and safe in the treatment of persistent allergic rhinitis.

Full description

The trial consists of 5 treatment sessions along with a one-year follow-up. This process is then repeated in the second and third years. Eligible participants diagnosed with PAR were randomized at a ratio of 2:2:1 into one of three groups: (a) SHP group; (b) placebo group; or (c) waiting-list group. The waiting-list group will receive no treatment in the first year, but will receive SHP in the following two years. The primary outcome, total nasal symptoms score, is self-assessed at the beginning of each treatment session and during each annual follow-up. Secondary outcomes include the Rhinoconjunctivitis Quality of Life Questionnaire, allergic rhinitis attacks, and relief medications. The trial will be stopped if early termination criteria are met during the interim analysis.

Enrollment: 453 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• aged ≥18 with PAR, defined clinically as symptoms being present at least 4 days a week, for at least 4 weeks
• Test positive for allergen specific immunoglobulin E . Allergens include: mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae), cockroach (Blatella germanica) and/or house dust
• Informed consent
• TNSS ≥3

Exclusion criteria

• Seasonal or chronic instance of other forms of rhinitis (i.e. sinusitis)
• Asthma and/or moderate to severe atopic dermatitis
• Allergy treatment at present due to asthma, eczema, atopic dermatitis, or other diseases
• Nasal structural abnormalities
• Severe mental illness, severe chronic respiratory diseases, severe diseases of the cardiovascular system, severe kidney disease, severe liver disease, severe blood system diseases, severe neurological and neuromuscular disease, severe metabolic and endocrine system disease, severe diabetes, immune function (including the application of immunosuppressant or HIV infection to low immune function etc.); The laboratory test indexes more than twice the upper limit of normal reference value or abnormal results that don't fit for the study confirmed by researchers;
• Blood coagulation dysfunction or patients are using anticoagulants
• Systemic corticosteroids treatment six months before the start of the study, or intranasal corticosteroids 15 days before the start of the study;
• Immunotherapy for more than 3 years;
• Alternative therapies such as acupuncture, traditional Chinese medicine (TCM) one month before the start of the study,or prepare to use during the study;
• Moxibustion therapy half years before the start of the study;
• Patients participating other clinical trials;
• Prepare to pregnancy, pregnancy or lactation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

453 participants in 3 patient groups, including a placebo group

Sanfujiu

Experimental group

Description:

Formula for Sanfujiu: Huangjiezi; Xixin; Yanhusuo; and so on Acupoint for Sanfujiu: Different ten acupoints determined according to Chinese medicine theory for each time. Timepoint: Five times of 3 years at Sanfu Point application: The patients will be treated with herbal cake-separated moxibustion on acupoints and lasted 60 minutes each time.

Treatment:

Drug: Sanfujiu

placebo

Placebo Comparator group

Description:

Formula for placebo: Fuxiaomai; and so on. the appearance is similar as drugs of Sanfujiu Acupoint for placebo: Ten acupoints determined according to Chinese medicine theory are the same as Sanfujiu group of each timepoint . Timepoint: Five times per year for 3 years. Point application: The patients will be treated with placebo on acupoints and lasted 60 minutes each time.

Treatment:

Drug: Placebo

waiting list

No Intervention group

Description:

No intervention in the first year. Accept Sanfujiu in the second and the third years.